Associated tags: Diagnosis, Protein, Health, Medicine, Patient, Proteomics, Biomarker, Research, PEA
Locations: HT, UPPSALA, SE, II, EU, SWEDEN, MA
USD,
Annual general meeting,
LTI,
Annual,
Remuneration,
Auditor,
Consultant,
Exercise,
Audit committee,
Committee,
Nomination,
AGM UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg.
Key Points:
- UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg.
- no 559189-7755, (the “Company”), on 19 April 2024 the AGM adopted, inter alia, the following resolutions.
- The AGM also discharged the Board Members and the CEO from liability for the financial year 2023.
- Payment shall be able to be made in cash, in kind, by offset or otherwise in accordance with other conditions.
UKB,
Health,
Kingdom of Poland,
Prostate cancer,
Chronic lymphocytic leukemia,
CLL,
Disease,
Partnership,
Risk,
Biomarker,
Research,
FCRL2,
Protein,
Biology,
Medicine,
Biobank,
Data,
UK Biobank,
Pharmaceutical industry In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over 50,000 samples analyzed using the Olink® Explore platform.
Key Points:
- In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over 50,000 samples analyzed using the Olink® Explore platform.
- The UKB-PPP is the largest population-scale proteomics study to date, yielding an unprecedented view into the biology of diseased and healthy individuals over a 10-year period.
- By combining protein measurements with longitudinal healthcare data for each of the individuals, Olink derived the estimated effects of ~3,000 proteins on the future risk of disease.
- Olink Insight is a free, web-based platform that puts the results of advanced computational data analysis into the hands of non-data scientists.
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at https://investors.olink.com/ .
Key Points:
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at https://investors.olink.com/ .
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023.
Key Points:
- UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023.
- Analysis services revenue for the fourth quarter of 2023 was $23.2 million, as compared to $23.4 million for the fourth quarter of 2022.
- Other revenue was $5.7 million for the fourth quarter of 2023, as compared to $3.9 million for the fourth quarter of 2022.
- Reported gross profit was $48.7 million in the fourth quarter of 2023, as compared to $43.1 million in the fourth quarter of 2022.
Exercise,
Euroclear,
Electoral roll,
Category D,
USD,
Audit committee,
Employment,
Audit,
Welfare,
Policy,
Annual general meeting,
Tier,
Minutes,
Privacy,
Person,
Report,
Consolidated,
Plan,
Proxy,
Social Security,
Meeting,
Swedish,
RSU,
Consultant,
Auditor,
Committee,
LTI,
Annual report,
European Parliament,
Address,
ADS,
Units of paper quantity,
Balance sheet,
Security (finance) UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg.
Key Points:
- UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg.
- 559189-7755, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CET on Friday the 19 April 2024, in the Company’s facilities at Salagatan 16A, Uppsala.
- Shareholders who do not wish to attend the meeting in person may authorize a proxy to exercise their voting rights.
- The power of attorney is proposed to be presented to the Chairman of the Meeting or another person whom the shareholder knows will attend the Annual General Meeting.
UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink’s 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden on April 19th, 2024. The AGM was previously scheduled to take place on April 17th, 2024.
Key Points:
UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink’s 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden on April 19th, 2024. The AGM was previously scheduled to take place on April 17th, 2024.
Retrieved on:
Wednesday, November 15, 2023
EBITDA,
Acquisition,
Research,
Thermo Fisher Scientific,
Signature,
Row,
Geography,
Growth,
Wall,
Video game,
Pharmaceutical industry,
Target UPPSALA, Sweden, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023.
Key Points:
- UPPSALA, Sweden, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023.
- Analysis services revenue for the third quarter of 2023 was $16.9 million, as compared to $15.1 million for the third quarter of 2022.
- Other revenue was $3.5 million for the third quarter of 2023, as compared to $3.2 million for the third quarter of 2022.
- Reported gross profit was $30.9 million in the third quarter of 2023, as compared to $21.0 million in the third quarter of 2022.
Metagenomics,
MD,
Doctor of Philosophy,
Research,
Protein,
Epigenomics,
Genomics,
NGS,
Gene,
Proteomics,
HT,
Marketing The addition of Olink Explore HT significantly increases Novogene AMEA's capabilities and quality of multi-omics research services offerings.
Key Points:
- The addition of Olink Explore HT significantly increases Novogene AMEA's capabilities and quality of multi-omics research services offerings.
- Olink Explore HT represents the state of the art in next generation proteomics, allowing scientists to accurately measure over 5,400 proteins using only 2µl of sample.
- “The addition of the Olink Explore platform to the Novogene portfolio marks our commitment to delivering the latest multi-omics solutions to the scientific community in Asia Pacific, Middle East and Africa region.
- Now, with Olink Explore HT, Novogene AMEA will begin offering high-throughput proteomics with industry-leading specificity, helping their customers unravel the intricate connections between genes, proteins, and diseases.
Retrieved on:
Thursday, October 5, 2023
Drug repositioning,
Health,
UK Biobank,
Biomarker,
Drug development,
Proteogenomics,
Data,
Proteomics,
Safety,
UKB,
Kingdom of Poland,
CV,
AstraZeneca,
GWAS,
Gene,
Protein,
Publication,
Drug discovery,
Biobank,
Volunteering,
Genomics,
Research,
Sun,
Vaccine,
Pharmaceutical industry,
Nature The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.
Key Points:
- The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.
- Using the Olink Explore platform, researchers measured around 3,000 proteins in more than 54,000 UKB participant samples.
- The findings illustrate the immense value of proteogenomics in elucidating biological mechanisms, identifying actionable new biomarkers, and accelerating drug development efforts.
- “These landmark publications are a powerful demonstration of how next-gen proteomics can reveal crucial biological insights not seen with traditional genomics alone.
Retrieved on:
Tuesday, September 19, 2023
Drug development,
University,
Area studies,
Workflow,
Associate professor,
University of Florida,
Research,
Biomarker,
Proteomics,
Mouse,
Biology,
Immunology,
Infection,
Vaccine Uppsala, Sweden, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
Key Points:
- Uppsala, Sweden, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
- The Olink Target 48 Mouse Cytokine Panel represents a new standard in immunoassays giving researchers the ability to accurately measure 43 carefully selected immune-related proteins using as little as 1µl of sample volume.
- Its performance surpasses other platforms available in the market that we have tried.”
The Olink Target 48 Mouse Cytokine Panel was designed to deliver an in-depth view of cytokine signalling and inflammatory pathways for pre-clinical and translational research.
- Olink Target 48 Mouse Cytokine Panel is fully compatible with the Olink® Signature Q100, a high performance, auto-calibrated instrument for data readout that facilitates unattended operation.
